Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.

Kearns, Donovan G; Chat, Vipawee S; Uppal, Shelley; Wu, Jashin J

Kearns, Donovan G; Chat, Vipawee S; Uppal, Shelley; Wu, Jashin J.

Kearns DG; Loma Linda University School of Medicine, Loma Linda, California.
Chat VS; Medical College of Georgia at Augusta University, Augusta, California.
Uppal S; Albany Medical College School of Medicine, Albany, New York.
Wu JJ; Dermatology Research and Education Foundation, Irvine, California. Electronic address: jashinwu@gmail.com.

J Am Acad Dermatol ; 83(6): e433-e434, 2020 Dec.

Article in English | MEDLINE | ID: covidwho-688885

Subject(s)

Adalimumab/adverse effects; Coronavirus Infections/epidemiology; Hidradenitis Suppurativa/drug therapy; Immunosuppressive Agents/adverse effects; Pneumonia, Viral/epidemiology; Betacoronavirus/immunology; COVID-19; Coronavirus Infections/immunology; Coronavirus Infections/prevention & control; Coronavirus Infections/virology; Hidradenitis Suppurativa/immunology; Humans; Pandemics/prevention & control; Pneumonia, Viral/immunology; Pneumonia, Viral/prevention & control; Pneumonia, Viral/virology; Randomized Controlled Trials as Topic; Risk Assessment; SARS-CoV-2; Tumor Necrosis Factor-alpha/antagonists & inhibitors; Tumor Necrosis Factor-alpha/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Hidradenitis Suppurativa / Coronavirus Infections / Adalimumab / Immunosuppressive Agents Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: J Am Acad Dermatol Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google